WuXi Biologics Selected as Constituent of FTSE4Good Index Series for Fifth Consecutive Year
WuXi Biologics (WXXWY), a global Contract Research, Development, and Manufacturing Organization (CRDMO), has been selected as a constituent of the FTSE4Good Index Series for the fifth consecutive year, recognizing its outstanding sustainability performance.
The company has demonstrated exceptional performance in ESG ratings, particularly in corporate governance, anti-corruption, labor standards, and water security. WuXi Biologics has received multiple sustainability recognitions, including an EcoVadis Platinum Medal, listing in Dow Jones Sustainability Indices, and CDP Water Security "A List" status. The company's new greenhouse gas emissions reduction targets have been approved by the Science Based Targets initiative (SBTi).
WuXi Biologics (WXXWY), un'azienda globale di Ricerca, Sviluppo e Produzione su contratto (CRDMO), è stata selezionata come costituente della serie di indici FTSE4Good for fifth consecutive year, riconoscendo la sua eccezionale performance di sostenibilità. L'azienda ha dimostrato una performance eccezionale nelle valutazioni ESG, in particolare in governance aziendale, lotta alla corruzione, standard lavorativi e sicurezza idrica. WuXi Biologics ha ricevuto numerosi riconoscimenti per la sostenibilità, tra cui una medaglia EcoVadis Platino, l'inserimento negli indici Dow Jones Sustainability e lo status CDP Water Security "A List". I nuovi obiettivi di riduzione delle emissioni di gas serra dell'azienda sono stati approvati dall'iniziativa Science Based Targets (SBTi).
WuXi Biologics (WXXWY), una organización global de Investigación, Desarrollo y Fabricación por contrato (CRDMO), ha sido seleccionada como miembro de la FTSE4Good Index Series por quinto año consecutivo, reconociendo su destacada sostenibilidad. La empresa ha mostrado un rendimiento excepcional en las calificaciones ESG, especialmente en gobernanza corporativa, lucha contra la corrupción, normas laborales y seguridad hídrica. WuXi Biologics ha recibido múltiples reconocimientos en sostenibilidad, incluyendo la Medalla de Platino EcoVadis, su inclusión en los Dow Jones Sustainability Indices y el estatus "A List" de CDP Water Security. Los nuevos objetivos de reducción de emisiones de gases de efecto invernadero de la empresa han sido aprobados por la iniciativa Science Based Targets (SBTi).
WuXi Biologics (WXXWY)은 글로벌 계약 연구개발 및 제조기관(CRDMO)으로서 다섯 번째 연속으로 FTSE4Good Index Series의 구성 종목으로 선정되어 지속가능성 실적을 인정받았습니다. 회사는 특히 기업지배구조, 반부패, 노동기준, 수자원 보안 부문에서 ESG 평가에 있어 뛰어난 성과를 보였습니다. WuXi Biologics는 EcoVadis Platinum Medal, Dow Jones Sustainability Indices 등재, CDP Water Security "A List" 등 다수의 지속가능성 인정을 받았습니다. 회사의 새로운 온실가스 배출 감소 목표는 Science Based Targets initiative(SBTi)의 승인을 받았습니다.
WuXi Biologics (WXXWY), une organisation mondiale de Recherche, Développement et Fabrication sous contrat (CRDMO), a été sélectionnée comme constituante de la série d’indices FTSE4Good pour la cinquième année consécutive, en reconnaissance de sa performance durable exceptionnelle. L'entreprise a démontré une performance exceptionnelle dans les notations ESG, notamment en gouvernance d'entreprise, lutte contre la corruption, normes du travail et sécurité de l'eau. WuXi Biologics a reçu de multiples distinctions en matière de durabilité, dont la médaille EcoVadis Platinum, l’inscription dans les Dow Jones Sustainability Indices et le statut CDP Water Security « A List ». Les nouveaux objectifs de réduction des émissions de gaz à effet de serre de l’entreprise ont été approuvés par l’initiative Science Based Targets (SBTi).
WuXi Biologics (WXXWY), ein globales Contract Research, Development and Manufacturing Organization (CRDMO), wurde als Bestandteil der FTSE4Good Index Series für das fünfte aufeinanderfolgende Jahr ausgewählt, um seine herausragende Nachhaltigkeitsleistung anzuerkennen. Das Unternehmen hat in ESG-Bewertungen außergewöhnliche Leistungen gezeigt, insbesondere in Unternehmensführung, Anti-Korruption, Arbeitsstandards und Wassersicherheit. WuXi Biologics hat mehrere Nachhaltigkeit-Auszeichnungen erhalten, darunter eine EcoVadis-Platin-Medaille, die Aufnahme in die Dow Jones Sustainability Indices und den CDP Water Security „A List“-Status. Die neuen Treibhausgas-Emissionsreduktionsziele des Unternehmens wurden von der Science Based Targets initiative (SBTi) genehmigt.
WuXi Biologics (WXXWY)، شركة أبحاث وتطوير وتصنيع تعاقدية عالمية (CRDMO)، اختيرت كعضو في سلسلة FTSE4Good للمؤشرات للسنة الخامسة على التوالي، اعترافاً بأدائها المستدام المتفوق. أظهرت الشركة أداءً استثنائياً في تصنيفات ESG، خاصة في حوكمة الشركات، مكافحة الفساد، معايير العمل، وأمن المياه. حصلت WuXi Biologics على العديد من جوائز الاستدامة، بما في ذلك ميدالية EcoVadis البلاتينية، إدراجها في Dow Jones Sustainability Indices، ووضع CDP Water Security "A List". كما تمت الموافقة على أهداف الشركة الجديدة لتقليل انبعاثات الغازات الدفيئة من قبل مبادرة Science Based Targets (SBTi).
WuXi Biologics (WXXWY)，是一家全球合同研究、开发与制造机构（CRDMO），已连续第五年被选为 FTSE4Good 指数系列成分股，表彰其卓越的可持续发展表现。公司在环境、社会与治理（ESG）评分方面表现突出，特别是在公司治理、反腐败、劳动标准以及水资源安全方面。WuXi Biologics 已获得多项可持续发展荣誉，包括 EcoVadis 铂金奖、入选道琼斯可持续性指数，以及 CDP 水资源安全“最佳名单（A List）”身份。公司的新温室气体排放削减目标已获 Science Based Targets initiative（SBTi）批准。
- None.
- None.
The FTSE4Good Index Series, launched in 2001 by FTSE Russell (now part of the London Stock Exchange Group), is a family of equity indices designed to measure the performance of companies demonstrating strong Environmental, Social, and Governance (ESG) practices. The Series serves as a benchmark for investors seeking to align their portfolios with sustainability goals.
Inclusion in the FTSE4Good Index Series is based on independent analysis of data from over 23 developed countries and 20 emerging countries. WuXi Biologics has consistently demonstrated exceptional performance in its FTSE Russell ESG ratings over the past five years, most specifically in the areas of corporate governance, anti-corruption, labor standards, and water security.
Dr. Chris Chen, CEO of WuXi Biologics and Chairman of its ESG Committee, commented, "We are very pleased to be selected again as a constituent of FTSE4Good Index Series, an acknowledgement that further inspires our steadfast dedication to driving sustainability. As a global leader in Green CRDMO, we consistently deliver ESG excellence, enable partners worldwide with end-to-end solutions, and work together with all stakeholders to promote sustainable practices."
In line with United Nations Sustainable Development Goals, WuXi Biologics has been actively engaged with United Nations Global Compact (UNGC) and Pharmaceutical Supply Chain Initiative (PSCI) to deliver positive impacts. Recently, the company's new near-term and net-zero greenhouse gas emissions reduction target matrix has been approved by Science Based Targets initiative (SBTi).
Over the past few years, WuXi Biologics has earned widespread recognition for its dedicated efforts in sustainability. The company was awarded EcoVadis Platinum Medal; listed in Dow Jones Sustainability Indices; named to CDP Water Security "A List" and Supplier Engagement Assessment "A List", and awarded a CDP Climate Change leadership-level "A-" score; given the highest negligible-risk rating by Sustainalytics, and recognized as Sustainalytics industry and regional ESG top-rated company; listed in Hang Seng ESG 50 Index; and rated as Prime by ISS ESG Corporate Rating.
About FTSE4Good Index Series
Created by the global index and data provider FTSE Russell, the FTSE4Good Index Series is designed to measure the performance of companies demonstrating strong Environmental, Social and Governance (ESG) practices. The FTSE4Good indexes are used by a wide variety of market participants to create and assess responsible investment funds and other products.
FTSE Russell evaluations are based on performance in areas such as Corporate Governance, Health & Safety, Anti-Corruption and Climate Change. Businesses included in the FTSE4Good Index Series meet a variety of environmental, social and governance criteria.
For more information, please visit: https://www.lseg.com/en/ftse-russell/indices/ftse4good.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK) is a leading global Contract Research, Development and Manufacturing Organization (CRDMO) offering end-to-end solutions that enable partners to discover, develop and manufacture biologics – from concept to commercialization – for the benefit of patients worldwide.
With over 12,000 skilled employees in
WuXi Biologics regards sustainability as the cornerstone of long-term business growth. The company continuously drives green technology innovations to offer advanced end-to-end Green CRDMO solutions for its global partners while consistently achieving excellence in Environment, Social and Governance (ESG). Committed to creating shared value, it collaborates with all stakeholders to foster positive social and environmental impacts and promote responsible practices that empower the entire value chain.
For more information about WuXi Biologics, please visit: www.wuxibiologics.com.
Contacts
Media
PR@wuxibiologics.com
View original content:https://www.prnewswire.com/news-releases/wuxi-biologics-selected-as-constituent-of-ftse4good-index-series-for-fifth-consecutive-year-302563765.html
SOURCE WuXi Biologics
FAQ
What is the significance of WuXi Biologics (WXXWY) being included in the FTSE4Good Index Series?
What ESG achievements has WuXi Biologics received in 2025?
What are WuXi Biologics' recent environmental commitments?
Which specific ESG areas has WuXi Biologics shown strong performance in?
